Plain-English translation of NCT04895709 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a brand-new cancer drug called in people whose cancer has progressed despite standard treatments. Researchers want to find the right dose and understand how well this medication works, either given by itself or combined with other well-known cancer drugs like nivolumab, , or . The trial is enrolling over 1,000 patients with many different types of advanced cancers.
Many people with advanced cancers stop responding to current standard treatments, and their options become limited. This medication targets a new pathway in cancer cells, and researchers hope it could help patients whose tumors have become resistant to existing therapies.
You likely qualify if…
You likely don't qualify if…
You would visit the study center regularly for check-ins, blood tests, and imaging scans to monitor how your cancer responds to the medication. Depending on which group you're assigned to, you'll take the new drug by itself or in combination with one or more other cancer medications. The trial includes a dose-escalation phase where researchers find the safest effective dose, followed by an expansion phase with more patients to confirm results. You'll also need to undergo tumor biopsies at specific timepoints so researchers can understand how the medication is affecting your cancer at a cellular level.
AI-generated summary from trial data · Aug 30, 2026 · Not medical advice
United States